Lymphoma

Lymphoma is one of the cancers where two separate questions decide the claim, and they don't move together. The first question is service connection: did the cancer arise from a qualifying exposure. For non-Hodgkin's lymphoma and Hodgkin's disease, the answer is often a presumptive yes, which is why these claims succeed more than the average cancer claim. The second question is the rating, and that's where veterans get blindsided. A lymphoma rating is not a permanent number. It is 100% while the disease is active and during the treatment phase, then it converts to a residual-based rating after a mandatory examination.

That conversion is the part that catches people. A veteran finishes chemotherapy, goes into remission, and assumes the 100% rating holds. It doesn't. The regulation builds in a re-examination at the end of the treatment-phase period, and the rating is then based on whatever residuals remain: peripheral neuropathy from chemotherapy, chronic fatigue, organ damage, immune compromise, secondary malignancies. If the residuals are minimal, the rating can drop sharply. The protection on the way down is procedural: any reduction has to follow the 38 CFR § 3.105(e) process, with notice and an opportunity to respond.

This page walks through both lymphoma diagnostic codes under 38 CFR § 4.117, DC 7709 for Hodgkin's disease and DC 7715 for non-Hodgkin's lymphoma, how the active-phase 100% rating works, how the residual-based conversion works after treatment ends, the Agent Orange and Camp Lejeune presumptive pathways that drive service connection, and the secondary residual conditions under 38 CFR § 3.310 that keep the rating up after the cancer itself goes quiet.

TL;DR

• Lymphoma is rated under 38 CFR § 4.117 (hemic and lymphatic systems): DC 7709 for Hodgkin's disease and DC 7715 for non-Hodgkin's lymphoma.
• Both codes carry a 100% evaluation while the disease is active or during a treatment phase.
• After treatment ends, the rating converts to a residual-based evaluation following a mandatory VA re-examination at the end of the treatment-phase period.
• Any reduction from the 100% rating must follow the 38 CFR § 3.105(e) procedure, which requires notice and a chance to respond before the lower rating takes effect.
• Non-Hodgkin's lymphoma is an Agent Orange presumptive under 38 CFR § 3.309(e) and is recognized in the Camp Lejeune contaminated-water context. Hodgkin's disease is likewise a herbicide presumptive.
• The strongest claims pair the pathology report (confirming the lymphoma subtype) with proof of qualifying exposure (herbicide, Camp Lejeune service dates).
• Residuals under § 3.310 keep the rating up after remission: chemotherapy-induced peripheral neuropathy, fatigue, secondary malignancies, immune compromise.
• In Claim Raven's analysis of 532 BVA lymphoma cases, 29.7% were granted, 33.6% were remanded, and 22.9% were denied. Of the 332 cases with a C&P adequacy determination, 62.7% had the exam flagged as inadequate.

The Two Diagnostic Codes and the 100% Active-Disease Rating

The hemic and lymphatic section of 38 CFR § 4.117 handles lymphoma through two codes that work the same way structurally.

DC 7709, Hodgkin's disease. This covers Hodgkin's lymphoma, the form historically defined by Reed-Sternberg cells on biopsy.

DC 7715, Non-Hodgkin's lymphoma. This is the larger and more varied category, covering the many B-cell and T-cell lymphomas that are not Hodgkin's. It is also the code most often in play in exposure-based claims, because non-Hodgkin's lymphoma is the presumptive form tied to Agent Orange and Camp Lejeune.

Both codes follow the same two-phase logic that VA uses across most active malignancies:

A 100% evaluation is assigned with active disease or during a treatment phase. The 100% rating continues beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating is determined by a mandatory VA examination. Any change in evaluation based upon that or any subsequent examination is subject to the provisions of § 3.105(e).

The practical meaning: while the lymphoma is active, or while you are in chemotherapy, radiation, or other antineoplastic treatment, you are rated at 100%. That rating does not stop the day treatment stops. It continues through the treatment phase and into a defined window afterward, and only then does the mandatory examination determine what comes next. I describe the six-month window qualitatively here because the exact trigger point is set by the regulation and the treatment record, not by anything the veteran controls. The point to hold onto is that the 100% does not evaporate at the last chemo session.

The Conversion to Residuals: Where the Rating Actually Lands

This is the part of a lymphoma claim that is most often misunderstood, and where the real fight usually happens.

After the treatment-phase period ends, VA schedules a mandatory examination. The 100% rating is then replaced by a rating based on residuals. There is no presumptive floor in DC 7709 or DC 7715 the way DC 5055 gives knee replacements a 30% minimum. Instead, the residuals are rated under whatever diagnostic codes fit the actual damage left behind.

That means the post-treatment rating can be anything from 100% down to 0%, depending entirely on what the examination documents. A veteran with significant residual organ damage, severe peripheral neuropathy, and disabling fatigue can hold a high combined rating. A veteran who reads as fully recovered on a thin examination can drop to a very low rating or zero.

The procedural protection is real but limited. Under 38 CFR § 3.105(e), VA cannot simply lower the rating. It has to issue a proposed reduction, give the veteran 60 days to submit evidence and request a hearing, and only then implement the change, with the reduction taking effect on a delayed schedule. If VA skips those steps, the reduction is procedurally defective and can be reversed on appeal regardless of the medical merits. I see procedural-reduction arguments succeed in the dataset even where the underlying medical picture was genuinely improved, because § 3.105(e) is a notice rule, not a medical one.

The substantive defense against a reduction is different from the procedural one. To sustain a reduction, the record has to show actual sustained improvement in the condition under ordinary conditions of life, not just a single better-looking snapshot. A one-day examination that captures a good day does not establish material improvement. This is the lymphoma analogue to the flare-up problem in orthopedic claims: the snapshot is not the disability.

The Presumptive Pathways: Why Lymphoma Claims Win

Service connection is the part of a lymphoma claim that goes better than most cancers, and it is almost entirely because of the presumptive pathways. When the cancer type matches a recognized exposure, the veteran does not have to prove a medical nexus from scratch. The law presumes the connection.

Agent Orange and herbicide exposure. Non-Hodgkin's lymphoma is on the list of conditions presumptively connected to herbicide exposure under 38 CFR § 3.309(e). Hodgkin's disease is likewise a herbicide presumptive. For a veteran with qualifying exposure, which after the PACT Act includes a substantially expanded set of locations and service periods beyond the original Vietnam boots-on-ground definition, the presumption does the heavy lifting. You establish the qualifying service, you establish the lymphoma diagnosis by pathology, and the connection is presumed. There is no need for a private nexus opinion tying the cancer to the herbicide.

Camp Lejeune contaminated water. Non-Hodgkin's lymphoma is also recognized in the Camp Lejeune contaminated-water context. Veterans, and in some programs family members, who served or resided at Camp Lejeune during the contamination period and later developed non-Hodgkin's lymphoma have a recognized exposure-to-disease pathway. The proof here is service or residence dates at Camp Lejeune within the qualifying window plus the pathology-confirmed diagnosis.

What both pathways require, and what gets missed, is documentation of two distinct facts: the qualifying exposure and the lymphoma subtype. The pathology report matters because the presumptions are subtype-specific. Non-Hodgkin's lymphoma is presumptive; a generic "lymphoma" note in a primary care record without the biopsy classification gives the rater a reason to ask for development rather than grant. The cases that move fastest attach the biopsy or oncology report that names the diagnosis precisely, alongside the exposure proof (service records, unit location, Camp Lejeune dates).

Secondary and Residual Conditions Under 38 CFR § 3.310

Once the active cancer resolves, the rating depends on residuals, and residuals are also where secondary service connection under 38 CFR § 3.310 comes in. A condition caused or aggravated by the service-connected lymphoma, or by its treatment, can be separately service-connected (aggravation recognized under Allen v. Brown). For lymphoma, the most common residual and secondary chains are:

Chemotherapy-induced peripheral neuropathy. Several lymphoma chemotherapy regimens are neurotoxic and leave veterans with chronic peripheral neuropathy in the hands and feet: numbness, burning, weakness, loss of sensation. This is rated under the peripheral nerve codes and is frequently the single largest residual rating after remission. It is also frequently under-documented because the treating oncologist focuses on the cancer, not the nerves. A veteran reporting persistent numbness after chemo should make sure that complaint is in the record and tied to the treatment.

Chronic fatigue and weakness. Disabling fatigue is a common and durable residual of both the disease and its treatment. It is harder to rate cleanly because fatigue maps onto multiple body systems, but it is a real functional loss that belongs in the post-treatment examination.

Secondary malignancies. Some lymphoma treatments, particularly radiation and certain chemotherapy agents, carry a long-term risk of secondary cancers. A secondary malignancy that develops as a consequence of the service-connected lymphoma or its treatment is itself a candidate for secondary service connection under § 3.310.

Immune compromise. Lymphoma and its treatment can leave lasting immune deficiency, with recurrent infections and downstream complications. Where that immune compromise produces a separately ratable condition, the chain runs through § 3.310.

The standard for any of these is the same as in every secondary claim: a medical opinion that identifies the mechanism, addresses the time course, and explains why the residual is caused or aggravated by the service-connected lymphoma or its treatment rather than by an unrelated cause. A bare assertion does not carry it; a reasoned opinion does.

C&P Exam Mechanics: What the Examiner Has to Address

The lymphoma C&P examination carries unusual weight because it is the examination that converts the 100% active rating into a residual rating. A thin examination here costs the veteran directly.

A complete examination should document:

• The current status of the lymphoma: active, in remission, in surveillance, or relapsed, with the supporting oncology records.
• The treatment history and the date treatment ended, which anchors the treatment-phase calculation that determines whether the 100% rating still applies.
• Each residual separately: peripheral neuropathy (which nerves, severity, sensory versus motor), fatigue and its functional impact, organ damage, immune status, and any secondary condition.
• Objective findings tied to each residual, not a global "in remission, no residuals" conclusion that flattens the picture.

The failure mode is an examination that confirms remission and stops. Remission answers the cancer question; it does not answer the residual question. When the examiner does not separately evaluate neuropathy, fatigue, and other residuals, the rating defaults low, and the veteran is left appealing on the strength of records the examiner should have considered the first time.

That dynamic shows up hard in the data. Of the 332 lymphoma cases in Claim Raven's dataset that carried a C&P adequacy determination, 62.7% had the examination flagged as inadequate. That is a high inadequacy rate, and it is consistent with the structural problem: the examination has to do two jobs, confirm cancer status and inventory residuals, and the residual inventory is the part that gets shortchanged.

Common Evidence Gaps in Lymphoma Claims

A few patterns I see repeatedly across BVA lymphoma decisions.

Missing or imprecise pathology. The presumptions are subtype-specific. A record that says "history of lymphoma" without the biopsy classification leaves the rater unable to apply the non-Hodgkin's presumption cleanly. The fix is the actual pathology or oncology report naming the diagnosis. This gap is one reason cases get remanded rather than granted outright.

Exposure not documented. Even when the cancer type is presumptive, the exposure has to be established. Vietnam-era veterans sometimes lack unit records placing them in a qualifying location, and Camp Lejeune claims need service or residence dates inside the contamination window. The presumption is only as good as the exposure proof behind it.

Residuals not separately claimed or examined. This is the big one after treatment ends. Veterans assume the lymphoma rating covers everything, so they never separately claim the chemotherapy-induced neuropathy or the chronic fatigue. When the 100% converts to a residual rating, there is nothing in the file documenting the residuals, and the rating drops further than it should.

Treating the 100% as permanent. A veteran who does not understand the treatment-phase conversion can be caught off guard by the mandatory re-examination and the proposed reduction. The defense, both procedural under § 3.105(e) and substantive (no sustained material improvement), works far better when the veteran responds inside the notice window with residual documentation rather than after the reduction is final.

Reduction notice defects. On the VA side, reductions from the 100% rating sometimes skip the § 3.105(e) steps. Where the proposed-reduction notice, the 60-day period, or the hearing opportunity is missing, the reduction is procedurally defective and can be reversed on that basis alone.

I do not know the exact share of lymphoma claims that carry any one of these gaps. What I can say from Claim Raven's analysis of 532 BVA lymphoma cases is that remands ran at 33.6%, the single largest outcome category, ahead of the 29.7% grant rate and the 22.9% denial rate, and that 62.7% of the cases with a C&P adequacy determination had the examination flagged as inadequate. That pattern is consistent with the evidence dynamics above: the Board is sending these cases back for more development, most often on the residual and examination-adequacy questions, more often than it is granting or denying outright.

Bottom Line

Lymphoma claims split into two questions that move independently. Service connection is the easier one: for non-Hodgkin's lymphoma and Hodgkin's disease, the Agent Orange and Camp Lejeune presumptives mean a documented exposure plus a pathology-confirmed diagnosis usually carries the connection without a private nexus opinion. The rating is the harder one. The 100% evaluation under DC 7709 or DC 7715 holds during active disease and the treatment phase, then converts to a residual-based rating after a mandatory examination. That conversion is where ratings fall, and the protection on the way down is partly procedural (§ 3.105(e) notice) and partly substantive (no reduction without sustained improvement). The veterans who hold a meaningful rating after remission are the ones who documented the residuals, the chemotherapy-induced neuropathy, the fatigue, the secondary conditions under § 3.310, before the re-examination, not after the reduction notice arrived. Same cancer, different paper trail, different long-term rating.

Related Conditions

Lymphoma sits alongside the other cancers in Claim Raven's oncology set, which share the same two-phase 100%-then-residuals structure under § 4.117 and § 4.115b and the same presumptive-exposure logic. See leukemia, another hemic and lymphatic malignancy with overlapping Agent Orange and Camp Lejeune pathways, and the solid-tumor cancers that follow the same active-then-residual rating pattern: lung cancer, prostate cancer, and colon cancer. Veterans converting from a 100% active rating to a residual rating should review the secondary conditions tool and document chemotherapy and radiation residuals before the mandatory re-examination.

Methodology and Limitations

• Data source: Rating criteria from 38 CFR § 4.117, DC 7709 (Hodgkin's disease) and DC 7715 (non-Hodgkin's lymphoma). Reduction procedure from § 3.105(e). Presumptive service connection from § 3.309(e) (herbicide) and the Camp Lejeune contaminated-water provisions. Secondary service connection from § 3.310, with aggravation under Allen v. Brown.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 532 lymphoma cases. Within that lymphoma subset, outcomes ran 29.7% granted (158 cases), 33.6% remanded (179 cases), and 22.9% denied (122 cases). Of the 332 cases that carried a C&P adequacy determination, 62.7% had the examination flagged as inadequate.
• Classification approach: Diagnostic code definitions drawn from the regulatory text of § 4.117. The two-phase rating structure (active/treatment 100%, then residual-based after mandatory examination) follows the regulation. Presumptive analysis follows § 3.309(e) and the Camp Lejeune provisions.
• Limitations:
• Compensation outcomes depend on documented residuals after treatment ends. There is no minimum residual rating floor in DC 7709 or DC 7715, so post-treatment ratings vary widely.
• The exact treatment-phase window and re-examination timing are set by the regulation and the individual treatment record. I describe the six-month window qualitatively rather than as a fixed date that applies to every case.
• Presumptive eligibility depends on the specific exposure facts (qualifying location and service dates) and the precise lymphoma subtype on pathology. The presumptions are subtype-specific.
• Selection bias: BVA-level patterns reflect cases that appealed. Most lymphoma claims resolve at the RO level and are not in any BVA dataset.
• The C&P inadequacy figure (62.7%) is computed only over the 332 cases that carried an adequacy determination, not over all 532 cases.
• These observations reflect patterns from the regulatory text, presumptive provisions, and BVA decisions. They are not predictions of individual outcomes.